Effects of edaravone on human neutrophil function

Acta Anaesthesiologica Scandinavica

Volumn 49, Issue 3, 2005, Pages 385-389

  Mikawa, K ^a   Akamatsu, H ^a   Nishina, K ^b   Obara, H ^a   Niwa, Y ^c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Niwa Institute for Immunology   (Japan)

Author keywords

Calcium ion; Chemotaxis; Edaravone; Free radical; Immunology; Neutrophil; Phagocytosis; Reactive oxygen species

Indexed keywords

CALCIUM ION; CHEMOTACTIC FACTOR; HYDROGEN PEROXIDE; HYDROXYL RADICAL; NORPHENAZONE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; XANTHINE OXIDASE;

ARTICLE; CALCIUM CELL LEVEL; CHEMOTAXIS; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG EFFECT; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE FUNCTION; NEUTROPHIL; NONPHOTOCHEMICAL QUENCHING; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANTIPYRINE; CALCIUM; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; HUMANS; HYDROGEN PEROXIDE; HYDROXYL RADICAL; NEUTROPHILS; PHAGOCYTOSIS; REACTIVE OXYGEN SPECIES; REFERENCE VALUES; XANTHINE; XANTHINE OXIDASE;

EID: 15944426135     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2005.00610.x     Document Type: Article

References (19)

1. Tabrizchi R. Edaravone Mitsubishi-Tokyo. Curr Opin Invest Drugs 2000; 1: 347-54.
2. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003; 15: 222-9.
3. Tanaka K, Fukuuchi Y, Nogawa S et al. Targets of treatment in the acute phase of cerebral infarction. Rinsho Shinkeigaku 2001; 41: 1052-4.
4. Tanaka M. Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent. Folia Pharmacol Jpn 2002; 119: 301-8.
5. Norris JW, Hachinski VC. High dose steroid treatment in cerebral infarction. Br Med J 1986; 292: 21-3.
6. Kelly JS, Sharkey J. Immunosuppressants-ligands as neuroprotectants. Transplant Proc 2001; 33: 2217-9.
7. Mankovsky BN, Metzger BE, Molitch ME, Biller J. Cerebrovascular disorders in patients with diabetes mellirus. J Diabetes Complicat 1996; 10: 228-42.
8. Minakami S, Kakinuma K, Takeshige K. Leukocytes and Biological Defence. Tokyo: Kodansha, 1990.
9. Mikawa K, Akamatsu H, Nishina K et al. The effect of phosphodiesterase III inhibitors on human neutrophil function. Crit Care Med 2000; 28: 1001-5.
10. Shibata H, Arai S, Izawa M et al. Phase I clinical study of MCI-186 (edaravone, 3-mefhyl-1-phenyl-2-pyrazolin-5-one) in healthy volunteers: safety and pharmacokinetics of single and multiple administrations. Jpn J Clin Pharmacol Ther 1998; 29: 863-6.
11. Klebanoff SJ, Rosen H. Ethylene formation by polymorphonuclear leukocytes. Role of myeloperoxidase. J Exp Med 1978; 148: 490-506.
12. Lerman J. Study design in clinical research: sample size estimation and power analysis. Can J Anaesth 1996; 43: 184-91.
13. Nishizuka Y. Studies and prospectives of the protein kinase c family for cellular regulation. Cancer 1989; 63: 1892-903.
14. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 312: 315-21.
15. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Anti-oxidant effects of gold compounds. Br J Dermatol 1987; 116: 39-46.
16. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1609-23.
17. Watanabe T, Hayashi K, Tamura F. Pharmacological effect of edaravone, a drug for cerebral protection. Rindho Yakubutsuchiryo 2002; 21: 686-92.
18. Tosaka M, Hashiba Y, Saito N et al. Contractile responses to reactive oxygen species in the canine basilar artery in vitro: selective inhibitory effect of MCI-186, a new hydroxyl radical scavenger. Acta Neurochir 2002; 144: 1305-10.
19. Wu TW, Zeng LH, Wu J, Fung KP. MCI-186: further histochemical and biochemical evidence of neuroprotection. Life Sci 2000; 67: 2387-92.